Treatment response of spirulina, omega-3 fatty acid and Vitamin E & C in OSMF

Clinical Correlation, Response to Treatment & Immunoexpression With Cross Talk Between c-JUN & TGF-Ã?Â² in Oral Submucous Fibrosis & Oral Cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/10/028530

Enrollment

Registered

2020-10-21

Start date

Unknown

Completion date

Unknown

Last updated

2022-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: - Health Condition 2: K135- Oral submucous fibrosis

Interventions

Intervention1: Tablet Spirulina 500 mg: Tablet Spirulina orally 500 mg twice daily for 6 months Control Intervention1: Capsule Omega-3 fatty acid: Capsule Omega-3 fatty acid orally 1gm twice daily for

Eligibility

Inclusion criteria

Inclusion criteria: Clinically and histopathologically proven cases of OSMF Restricted mouth opening

Exclusion criteria

Exclusion criteria: Patient not willing for participation Patient with severe systemic disease

Design outcomes

Primary

Measure	Time frame
Mouth Opening, Tongue Protrusion, Cheek Flexibility, VAS ScaleTimepoint: Pre treatment, 1 month, 3 months and at the end of 6 months	—

Secondary

Measure	Time frame
Reporting of any malignant transformation in the span of 6 monthsTimepoint: Every 4 weeks till 6 months	—

Countries

India

Contacts

Public ContactDr Ritu Garg

Maulana Azad Institute of Dental Sciences

drsunitagupta@yahoo.com9650174491

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026